Emerging drug development technologies targeting ubiquitination for cancer therapeutics
Open accessThe DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Abstract
Development of effective cancer therapeutic strategies relies on our ability to interfere with cellular processes that are dysregulated in tumors. Given the essential role of the ubiquitin proteasome system (UPS) in regulating a myriad of cellular processes, it is not surprising that malfunction of UPS components is implicated in numerous human diseases, including many types of cancer. The clinical success of proteasome inhibitors in treating multiple myeloma has further stimulated enthusiasm for targeting UPS proteins for pharmacological intervention in cancer treatment, particularly in the precision medicine era. Unfortunately, despite tremendous efforts, the paucity of potent and selective UPS inhibitors has severely hampered attempts to exploit the UPS for therapeutic benefits. To tackle this problem, many groups have been working on technology advancement to rapidly and effectively screen for potent and specific UPS modulators as intracellular probes or early-phase therapeutic agents. Here, we review several emerging technologies for developing chemical- and protein-based molecules to manipulate UPS enzymatic activity, with the aim of providing an overview of strategies available to target ubiquitination for cancer therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cisplatin in cancer therapy: Molecular mechanisms of action
Dasari, S., & Bernard Tchounwou, P. (2014) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2014.07.025 · Cited by 5,537 · cited 1×
“In non-small cell lung carcinoma cells, pimozide was shown to reverse the chemo-resistance observed with cisplatin (Chen, Dexheimer, et al., 2011) , a commonly used chemotherapy drug (Bloemink & Reedijk, 1996; Dasari & Tchounwou, 2014) with known resistance in Fanconi Anemia (Wang, 2007) .”
BackgroundA Phase 2 Study of Bortezomib in Relapsed, Refractory Myeloma
Richardson, P. G., Barlogie, B., Berenson, J., Singhal, S., Jagannath, S., Irwin, D., Rajkumar, S. V., Srkalovic, G., Alsina, M., Alexanian, R., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030288 · Cited by 2,632 · cited 1×
“1) for treatment of relapsed or refractory multiple myeloma (Richardson et al., 2003; Richardson, et al., 2005).”
BackgroundSakamoto, K. M., Kim, K. B., Kumagai, A., Mercurio, F., Crews, C. M., & Deshaies, R. J. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.141230798 · Cited by 2,609 · cited 3×
“Although these protein degraders induced rapid depletion of targets such as the methionine aminopeptidase-2, the estrogen receptor and androgen receptors (Sakamoto et al., 2001; Sakamoto et al., 2003) , the peptidic nature of the E3 ligase engager and its intrinsic instability posed limits for the application of the t…”
BackgroundMethodA comprehensive map of molecular drug targets
Santos, R., Ursu, O., Gaulton, A., Bento, A. P., Donadi, R. S., Bologa, C. G., Karlsson, A., Al-Lazikani, B., Hersey, A., Oprea, T. I., et al. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.230 · Cited by 2,427
Identification of a Primary Target of Thalidomide Teratogenicity
Ito, T., Ando, H., Suzuki, T., Ogura, T., Hotta, K., Imamura, Y., Yamaguchi, Y., & Handa, H. (2010) · Science · doi:10.1126/science.1177319 · Cited by 2,136
An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer
Soucy, T. A., Smith, P. G., Milhollen, M. A., Berger, A. J., Gavin, J. M., Adhikari, S., Brownell, J. E., Burke, K. E., Cardin, D. P., Critchley, S., et al. (2009) · Nature · doi:10.1038/nature07884 · Cited by 1,990 · cited 3×
“Penovedistat was developed from a medicinal chemistry approach aiming to improve on a previously discovered inhibitor, N6-benzyl adenosine, from a high-throughput screen (Soucy et al., 2009) .”
BackgroundInfluentialLenalidomide Causes Selective Degradation of IKZF1 and IKZF3 in Multiple Myeloma Cells
Krönke, J., Udeshi, N. D., Narla, A., Grauman, P., Hurst, S. N., McConkey, M., Svinkina, T., Heckl, D., Comer, E., Li, X., et al. (2014) · Science · doi:10.1126/science.1244851 · Cited by 1,879 · cited 1×
“Thalidomide was once well known for its adverse effects on fetus development before re-purposing for cancer therapy through binding to an E3 ligase Cereblon (CRBN) and stimulating lymphoid transcription factor ubiquitination and degradation (Ito et al., 2010; Kronke et al., 2014; Lu et al., 2014).”
BackgroundHow were new medicines discovered?
Swinney, D. C., & Anthony, J. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3480 · Cited by 1,812
The Myeloma Drug Lenalidomide Promotes the Cereblon-Dependent Destruction of Ikaros Proteins
Lu, G., Middleton, R. E., Sun, H., Naniong, M., Ott, C. J., Mitsiades, C. S., Wong, K.-K., Bradner, J. E., & Kaelin, W. G. (2014) · Science · doi:10.1126/science.1244917 · Cited by 1,583
Ubiquitin ligases: structure, function, and regulation
Zheng, N., & Shabek, N. (2017) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-060815-014922 · Cited by 1,499
Catalytic in vivo protein knockdown by small-molecule PROTACs
Bondeson, D. P., Mares, A., Smith, I. E. D., Ko, E., Campos, S., Miah, A. H., Mulholland, K. E., Routly, N., Buckley, D. L., Gustafson, J. L., et al. (2015) · Nature Chemical Biology · doi:10.1038/nchembio.1858 · Cited by 1,356
Structural basis of PROTAC cooperative recognition for selective protein degradation
Gadd, M. S., Testa, A., Lucas, X., Chan, K.-H., Chen, W., Lamont, D. J., Zengerle, M., & Ciulli, A. (2017) · Nature Chemical Biology · doi:10.1038/nchembio.2329 · Cited by 1,242 · cited 2×
“…and E3 engager - for achieving optimal target degradation has been described (Bondeson et al., 2015; Lai et al., 2016; Maniaci et al., 2017; Zengerle, Chan, & Ciulli, 2015), but the prominent role played by the linker geometry has emerged only recently (Burslem et al., 2018; Gadd et al., 2017).”
BackgroundSelective Small Molecule Induced Degradation of the BET Bromodomain Protein BRD4
Zengerle, M., Chan, K.-H., & Ciulli, A. (2015) · ACS Chemical Biology · doi:10.1021/acschembio.5b00216 · Cited by 1,056 · cited 1×
“…linker and E3 engager - for achieving optimal target degradation has been described (Bondeson et al., 2015; Lai et al., 2016; Maniaci et al., 2017; Zengerle, Chan, & Ciulli, 2015), but the prominent role played by the linker geometry has emerged only recently (Burslem et al., 2018; Gadd et al.,…”
Encoded combinatorial chemistry.
Brenner, S., & Lerner, R. A. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.12.5381 · Cited by 1,014 · cited 1×
“Research during these years also brought forth the generation of the fi rst DNA-encoded compound libraries (DECLs) (Brenner & Lerner, 1992; Kinoshita & Nishigaki, 1995) (Fig.”
BackgroundLessons in PROTAC Design from Selective Degradation with a Promiscuous Warhead
Bondeson, D. P., Smith, B. E., Burslem, G. M., Buhimschi, A. D., Hines, J., Jaime-Figueroa, S., Wang, J., Hamman, B. D., Ishchenko, A., & Crews, C. M. (2018) · Cell Chemical Biology · doi:10.1016/j.chembiol.2017.09.010 · Cited by 923 · cited 5×
“In fact, PROTACs based on promiscuous kinase inhibitors (Bondeson et al., 2018; H. T. Huang et al., 2018) were rendered more selective simply by engaging different E3 ligases, suggesting that the speci fi city of degradation induced by a PROTAC is mainly driven by the endogenous ligand speci fi city…”
BackgroundInfluentialAtypical antipsychotics: Mechanism of action
Seeman, P. (2002) · The Canadian Journal of Psychiatry · doi:10.1177/070674370204700106 · Cited by 899
Trends in the exploitation of novel drug targets
Rask-Andersen, M., Almén, M. S., & Schiöth, H. B. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3478 · Cited by 853 · cited 1×
“Although this approach has proven successful (Salami & Crews, 2017) , it has been limited by the number of druggable protein targets, accounting for onlỹ 3% of the human proteome (Dixon & Stockwell, 2009; Landry & Gies, 2008; Rask-Andersen, Almen, & Schioth, 2011; Santos et al., 2017; Uhlen et al., 2015) .”
Background53BP1 is a reader of the DNA-damage-induced H2A Lys 15 ubiquitin mark
Fradet-Turcotte, A., Canny, M. D., Escribano-Díaz, C., Orthwein, A., Leung, C. C. Y., Huang, H., Landry, M.-C., Kitevski-LeBlanc, J., Noordermeer, S. M., Sicheri, F., et al. (2013) · Nature · doi:10.1038/nature12318 · Cited by 686 · cited 1×
“We also developed a potent and highly selective UbV inhibitor of the tumor suppressor p53-binding protein 1 (53BP1), which recognizes ubiquitinated histone H2A and acts as a central regulator of the double-strand break repair pathway (Fradet-Turcotte et al., 2013) .”
BackgroundThe Advantages of Targeted Protein Degradation Over Inhibition: An RTK Case Study
Burslem, G. M., Smith, B. E., Lai, A. C., Jaime-Figueroa, S., McQuaid, D. C., Bondeson, D. P., Toure, M., Dong, H., Qian, Y., Wang, J., et al. (2018) · Cell Chemical Biology · doi:10.1016/j.chembiol.2017.09.009 · Cited by 686
Emergence of a DNA-damage response network consisting of Fanconi anaemia and BRCA proteins
Wang, W. (2007) · Nature Reviews Genetics · doi:10.1038/nrg2159 · Cited by 663 · cited 1×
“In non-small cell lung carcinoma cells, pimozide was shown to reverse the chemo-resistance observed with cisplatin (Chen, Dexheimer, et al., 2011), a commonly used chemotherapy drug (Bloemink & Reedijk, 1996; Dasari & Tchounwou, 2014) with known resistance in Fanconi Anemia (Wang, 2007).”
BackgroundSchneekloth, A. R., Pucheault, M., Tae, H. S., & Crews, C. M. (2008) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2008.07.114 · Cited by 635
DNA-encoded chemistry: enabling the deeper sampling of chemical space
Goodnow, R. A., Dumelin, C. E., & Keefe, A. D. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.213 · Cited by 621
Modular PROTAC design for the degradation of oncogenic BCR-ABL
Lai, A. C., Toure, M., Hellerschmied, D., Salami, J., Jaime‐Figueroa, S., Ko, E., Hines, J., & Crews, C. M. (2016) · Angewandte Chemie International Edition · doi:10.1002/anie.201507634 · Cited by 618 · cited 3×
“…of each PROTAC component - warhead, linker and E3 engager - for achieving optimal target degradation has been described (Bondeson et al., 2015; Lai et al., 2016; Maniaci et al., 2017; Zengerle, Chan, & Ciulli, 2015), but the prominent role played by the linker geometry has emerged only…”
BackgroundTargeted protein degradation by PROTACs
Neklesa, T. K., Winkler, J. D., & Crews, C. M. (2017) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.02.027 · Cited by 599 · cited 1×
“This shift from target inhibition to induced target destruction is exempli fi ed by proteolysis-targeting chimeras (PROTACs), small molecules that recruit a ubiquitin E3ligaseforproteindegradation(Lucas&Ciulli,2017;Neklesa,Winkler, & Crews, 2017; Toure & Crews, 2016).”
BackgroundMolecular basis of USP7 inhibition by selective small-molecule inhibitors.
Turnbull, A. P., Ioannidis, S., Krajewski, W. W., Pinto-Fernandez, A., Heride, C., Martin, A. C. L., Tonkin, L. M., Townsend, E. C., Buker, S. M., Lancia, D. R., et al. (2017) · Nature · doi:10.1038/nature24451 · Cited by 463
A Chemoproteomic Approach to Query the Degradable Kinome Using a Multi-kinase Degrader
Huang, H.-T., Dobrovolsky, D., Paulk, J., Yang, G., Weisberg, E. L., Doctor, Z. M., Buckley, D. L., Cho, J.-H., Ko, E., Jang, J., et al. (2018) · Cell Chemical Biology · doi:10.1016/j.chembiol.2017.10.005 · Cited by 437
Small-molecule hydrophobic tagging–induced degradation of HaloTag fusion proteins
Neklesa, T. K., Tae, H. S., Schneekloth, A. R., Stulberg, M. J., Corson, T. W., Sundberg, T. B., Raina, K., Holley, S. A., & Crews, C. M. (2011) · Nature Chemical Biology · doi:10.1038/nchembio.597 · Cited by 429
Protein Degradation by In-Cell Self-Assembly of Proteolysis Targeting Chimeras
Lebraud, H., Wright, D. J., Johnson, C. N., & Heightman, T. D. (2016) · ACS Central Science · doi:10.1021/acscentsci.6b00280 · Cited by 413 · cited 19×
“Regardless of the particular approach, inhibitor development with small-molecule HTS approaches depends on the solubility of chemical moieties (Erlanson, 2012).”
BackgroundInfluentialUSP7 small-molecule inhibitors interfere with ubiquitin binding.
Kategaya, L., Di Lello, P., Rougé, L., Pastor, R., Clark, K. R., Drummond, J., Kleinheinz, T., Lin, E., Upton, J.-P., Prakash, S., et al. (2017) · Nature · doi:10.1038/nature24006 · Cited by 333 · cited 2×
“What distinguished this work from previous studies, which pioneered the fi rst USP7 inhibitors (Kategaya et al., 2017; Pozhidaeva et al., 2017), was the use of me-dicinal chemistry to tailor initial screening hits.”
BackgroundMethodSmall‐Molecule Inhibitors of the Interaction between the E3 Ligase VHL and HIF1α
Buckley, D. L., Gustafson, J. L., Van Molle, I., Roth, A. G., Tae, H. S., Gareiss, P. C., Jorgensen, W. L., Ciulli, A., & Crews, C. M. (2012) · Angewandte Chemie International Edition · doi:10.1002/anie.201206231 · Cited by 302
Qin, C., Hu, Y., Zhou, B., Fernandez-Salas, E., Yang, C.-Y., Liu, L., McEachern, D., Przybranowski, S., Wang, M., Stuckey, J., et al. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00506 · Cited by 281 · cited 1×
“Limited in vivo data are available (Qin et al., 2018; Saenz et al., 2017) ; toxicity, pharmacokinetics, bioavailability, tissue distribution and metabolism of PROTAC molecules will require extensive investigation.”
BackgroundWaste disposal—An attractive strategy for cancer therapy
Salami, J., & Crews, C. M. (2017) · Science · doi:10.1126/science.aam7340 · Cited by 279 · cited 1×
“Although this approach has proven successful (Salami & Crews, 2017) , it has been limited by the number of druggable protein targets, accounting for onlỹ 3% of the human proteome (Dixon & Stockwell, 2009; Landry & Gies, 2008; Rask-Andersen, Almen, & Schioth, 2011; Santos et al., 2017; Uhlen et al., 2015) .”
BackgroundManiaci, C., Hughes, S. J., Testa, A., Chen, W., Lamont, D. J., Rocha, S., Alessi, D. R., Romeo, R., & Ciulli, A. (2017) · Nature Communications · doi:10.1038/s41467-017-00954-1 · Cited by 245 · cited 1×
“…component - warhead, linker and E3 engager - for achieving optimal target degradation has been described (Bondeson et al., 2015; Lai et al., 2016; Maniaci et al., 2017; Zengerle, Chan, & Ciulli, 2015), but the prominent role played by the linker geometry has emerged only recently (Burslem et…”
BackgroundUbiquitin in the immune system
Zinngrebe, J., Montinaro, A., Peltzer, N., & Walczak, H. (2014) · The EMBO Reports · doi:10.1002/embr.201338025 · Cited by 227
System-Wide Modulation of HECT E3 Ligases with Selective Ubiquitin Variant Probes
Zhang, W., Wu, K.-P., Sartori, M. A., Kamadurai, H. B., Ordureau, A., Jiang, C., Mercredi, P. Y., Murchie, R., Hu, J., Persaud, A., et al. (2016) · Molecular Cell · doi:10.1016/j.molcel.2016.02.005 · Cited by 168
Self-citationHarnessing the Ubiquitination Machinery to Target the Degradation of Specific Cellular Proteins
Zhou, P., Bogacki, R., McReynolds, L., & Howley, P. M. (2000) · Molecular Cell · doi:10.1016/s1097-2765(00)00074-5 · Cited by 164 · cited 1×
“Within the span of 20 years, high-throughput technologies further advanced to include feats in protein engineering such as proteolysis-targeting chimeras (PROTACs) derived from the ubiquitination pathway (Zhou, Bogacki, McReynolds, & Howley, 2000) , streamlined phage display approaches that include Ub variants (UbV) t…”
BackgroundPozhidaeva, A., Valles, G., Wang, F., Wu, J., Sterner, D. E., Nguyen, P., Weinstock, J., Kumar, K. G. S., Kanyo, J., Wright, D., et al. (2017) · Cell Chemical Biology · doi:10.1016/j.chembiol.2017.09.004 · Cited by 107
Codony-Servat, J., Tapia, M. A., Bosch, M., Oliva, C., Domingo-Domenech, J., Mellado, B., Rolfe, M., Ross, J. S., Gascon, P., Rovira, A., et al. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-05-0147 · Cited by 104
Ubiqutination via K27 and K29 chains signals aggregation and neuronal protection of LRRK2 by WSB1
Nucifora, F. C., Nucifora, L. G., Ng, C.-H., Arbez, N., Guo, Y., Roby, E., Shani, V., Engelender, S., Wei, D., Wang, X.-F., et al. (2016) · Nature Communications · doi:10.1038/ncomms11792 · Cited by 82
Identification and structure-guided development of pyrimidinone based USP7 inhibitors
O’Dowd, C. R., Helm, M. D., Rountree, J. S. S., Flasz, J. T., Arkoudis, E., Miel, H., Hewitt, P. R., Jordan, L., Barker, O., Hughes, C., et al. (2018) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.7b00512 · Cited by 71
Cited by
The role of ubiquitination in tumorigenesis and targeted drug discovery
Deng, L., Meng, T., Chen, L., Wei, W., & Wang, P. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-0107-0 · Cited by 744
PROTACs: great opportunities for academia and industry
Sun, X., Gao, H., Yang, Y., He, M., Wu, Y., Song, Y., Tong, Y., & Rao, Y. (2019) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-019-0101-6 · Cited by 613
He, Y., Zhang, X., Chang, J., Kim, H.-N., Zhang, P., Wang, Y., Khan, S., Liu, X., Zhang, X., Lv, D., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-15838-0 · Cited by 280
Targeting Lysosomal Degradation Pathways: New Strategies and Techniques for Drug Discovery
Pei, J., Wang, G., Feng, L., Zhang, J., Jiang, T., Sun, Q., & Ouyang, L. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01689 · Cited by 124
Metadata
- Authors
- Veggiani, G., Gerpe, M. C. R., Sidhu, S. S., & Zhang, W.
- Venue
- Pharmacology & Therapeutics
- Publisher
- Elsevier BV
- Published
- 2019-07
- Volume
- 199
- Pages
- 139-154
- ISSN
- 0163-7258 (ISSN-L)
- OpenAlex
- W2921123848
- Cited by
- 63
- References
- 40
- FWCI
- 3.22
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.